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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYGlioblastoma (GBM) is a lethalmalignancywhose clinical intransigence has been linked to extensive intraclonal genetic and phenotypic
diversity and the common emergence of therapeutic resistance. This interpretation embodies the implicit assumption that cancer stem
cells or tumor-propagating cells are themselves genetically and functionally diverse. To test this, we screened primary GBM tumors by
SNP array to identify copy number alterations (a minimum of three) that could be visualized in single cells by multicolor fluorescence
in situ hybridization. Interrogation of neurosphere-derived cells (from four patients) and cells derived from secondary transplants of
these same cells in NOD-SCID mice allowed us to infer the clonal and phylogenetic architectures. Whole-exome sequencing and sin-
gle-cell genetic analysis in one case revealed amore complex clonal structure. This proof-of-principle experiment revealed that subclones
in each GBM had variable regenerative or stem cell activity, and highlighted genetic alterations associated with more competitive prop-
agating activity in vivo.INTRODUCTION
Glioblastoma (GBM), the most common primary brain
cancer, is characterized by genetic instability and complex
evolutionary dynamics. Histopathological diversity gener-
ates various clinical phenotypes whose common feature is
the rapid emergence of treatment resistance to radiotherapy
and chemotherapy. Dominant clonal populations that
emerge as a result of genetic and epigenetic changes, which
confer a tumor survival advantage, drive tumor growth
(Nowell, 1976). Intratumor genetic and phenotypic hetero-
geneity is a hallmark of most cancers (Greaves and Maley,
2012; Marusyk et al., 2012) and is particularly marked in
GBM (Bonavia et al., 2011; Sottoriva et al., 2013; Patel
et al., 2014). Karyotypic (Shapiro et al., 1981) comparative
genomic hybridization (Jung et al., 1999) and fluorescence
in situ hybridization (FISH) screens (Little et al., 2012; Snu-
derl et al., 2011; Szerlip et al., 2012), as well as ultradeep, tar-
geted sequencing (Nickel et al., 2012), have documented the
intraclonal diversity of recurrent genetic abnormalities in
GBM, including theamplified receptor tyrosinekinasegenes
EGFR, PDGFRA, and MET. Genetic diversity of subclones is
likely to contribute to the clinical intransigence of GBM
(Nicholas, 2007), and therapeutic resistance of critical tu-
mor-propagating or stem cells is presumed to be pivotal to
this issue (Bao et al., 2006; Chen et al., 2010, 2012).
Subclonal evolution and cancer stem cells (CSCs) have
been considered as alternative mechanisms for disease pro-
gression (Shackleton et al., 2009), but it is also argued thatSthey are part of the same process because clonal diversity is
likely to be generated and sustained by genetically distinct
CSCs, which provide the units for evolutionary selection
(Greaves, 2013; Kreso and Dick, 2014). Evidence support-
ing this notion is found in acute lymphoblastic leukemia,
where subclonal genetic architecture has been linked to
the presence of genetically distinct stem cells assayed
in vivo by serial xenotransplantation (Anderson et al.,
2011; Notta et al., 2011). It seems likely a priori that GBM
would similarly harbor genetically diverse tumor stem/
propagating cell populations. This is supported by a previ-
ous study inwhich it was shown that distinct regions of the
same dissected GBM tumors had chromosomally distinct
(but clonally related) diversity, but were all expandable
in vitro under serum-free stem cell conditions and trans-
plantable in vivo as a readout of CSC (Piccirillo et al.,
2009). These data raise an important question about the
evolution of genetic diversity within the complex subclo-
nal structure of GBMs. Here, we conducted an analysis at
single-cell resolution of the genomic changes that occur
in GBM, and used competitive clonal phylogenies (Ander-
son et al., 2011) before and after xenotransplantation to
infer the genetics of stem/propagating cells in GBM.RESULTS AND DISCUSSION
Using the neurosphere protocol (Piccirillo et al., 2009),
we established stable patient-derived cell cultures fromtem Cell Reports j Vol. 4 j 7–15 j January 13, 2015 j ª2015 The Authors 7
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ble S1 available online). In order to exclude the possibility
of in vitro aberrations and culture selection, as soon as the
primary cells formed neurospheres, they were dissociated
into single cells and used for intracerebral transplantation
(and retransplantation) into NOD-SCID mice. We used
high-resolution SNP arrays performed on DNA extracted
from the primary GBM tumor cells to identify ‘‘driver’’
copy number alterations (CNAs), defined as recurrent re-
gions of amplification or deletion (Table S2). FISH probes
were designed for selected (preferably focal) CNAs, and
three-color FISH was applied to neurosphere cells as well
as cells isolated from tumors after secondary transplanta-
tion in NOD-SCID mice. We then compared the subclonal
genetic architecture and clonal phylogenies of the neuro-
spheres and the tumors generated in the mice. In all cases,
the driver CNAs chosen from analysis of tumor DNA were
present in the neurospheres and subclones that were pre-
sent in the mouse xenografts could be backtracked to the
original tumor, confirming the validity of this approach
for investigating clonal progression. A schematic overview
of the workflow is given in Figure S1.
Ten of the original 12GBMneurosphere cultures resulted
in tumors in the mice (Table S3). Four of these (GBM 2,
GBM 5, GBM 8, and GBM 11) had at least three ‘‘driver’’
lesions that could be tracked by FISH in both the neuro-
spheres and secondary xenografts in themice. The remain-
ing cases were not included because they had fewer than
three ‘‘trackable’’ lesions by SNP array (GBM 3 and GBM
6), because various aneuploid conditions were observed
in the derived neurosphere cell line (GBM 1) (Table S2),
or because there were too few cells for FISH at secondary
transplantation (GBM 4, GBM 7, and GBM 9). In all four
cases studied by multicolor FISH, there was genetic hetero-
geneity in the neurosphere cells, and each case showed a
unique, branched phylogenetic architecture. In each case,
more than one subclone was capable of propagating
tumors in secondary transplanted mice (Figures 1, 2, 3,
and 4).
Analyses of clonal architecture by multicolor FISH for
CNAs inevitably underestimate the extent of clonal diver-
sity (Anderson et al., 2011). In GBM 5, we had sufficient
material for a more detailed genetic analysis. The SNP ar-
rays of primary tumor GBM 5 revealed high-level, focal
amplification of EGFR; homozygous loss of CDKN2A (one
large deletion and one small focal deletion); and loss of
TP53 due to a deletion of 17p (Figure S2). We observed
seven subclones in the neurosphere cells and a branching
subclonal structure. The major clone in the neurospheres
had high-level focal amplification of EGFR, heterozygous
TP53, and homozygous CDKN2A loss. Only two subclones
read out in the secondary transplant tumor cells, and
both had high-level EGFR amplification and homozygous8 Stem Cell Reports j Vol. 4 j 7–15 j January 13, 2015 j ª2015 The AuthorsCDKN2A loss. In contrast to the neurospheres, the major
clone in the secondary mouse xenograft had two copies
of TP53. We performed mutation screening of the TP53
gene by capillary electrophoresis single-strand conforma-
tion analysis in primary patient tumor DNA, followed
by Sanger sequencing to characterize any mobility shifts
thus identified. This revealed a mutation in exon 5:
c.454C > T: p.152S. The same TP53 mutation was also
found in xenograft cells after secondary transplantation
(mouse 1 and mouse 3). Both wild-type and mutated
TP53 sequences were present in the tumor DNA, but only
the TP53 mutated sequence was present in the xenograft
DNA, indicating that the mutation was present in all sub-
clones of the mouse xenografts. In order to investigate
this further, we carried out whole-exome sequencing and
single-cell analysis for the simultaneous occurrence of
CNAs and selected single-nucleotide variants (SNVs) in
this case. For the latter, we used multiplex-targeted DNA
amplification of flow-sorted single cells followed by high-
throughput quantitative PCR (qPCR) using the BioMark
HD microfluidic platform (Potter et al., 2013).
Whole-exome sequencing of tumor DNA from GBM 5
identified a total of 32 SNVs (Table S3). A subset of these
SNVs was selected for single-cell analysis based on putative
gene function and variant allele fractions encompassing
high, low, and intermediate frequencies. The genomic tar-
gets selected included SNVs in KCNH5, PLCB2, GDF5,
TRMT5, TP53, and PALB2, and CNAs in CDKN2A, TP53,
and EGFR.
Single-cell analysis for the simultaneous presence of six
SNVs and three CNAswas carried out on flow-sorted neuro-
sphere and xenograft tumor cells from GBM 5 (a represen-
tative heatmap of the qPCR data from the BioMark HD is
given in Figure S3). A comparison of the clonal phylogeny
and subclonal architecture of neurosphere and xenograft
cells is shown in Figure 4. Homozygous CDKN2A deletion,
gain of EGFR (up to four copies), and KCN5, PLCB2, GDF5,
and TRMT5 mutations all occurred early and were present
in all subclones of the neurospheres (Figure 4A). Loss of
one TP53 wild-type allele occurred after EGFR amplifica-
tion of more than four copies. Heterozygous TP53 and
PALB2 mutations occurred after further EGFR amplifica-
tion. According to the chromosome 7 copy number as as-
sessed by FISH (Figure S4) and single-cell data (not shown),
EGFR gain was uncoupled from chromosome copy number
at three or four copies of chromosome 7. Subsequently,
there was an increasing gain of EGFR, consistent with
the formation of extrachromosomal double minutes. All
of the cells in the secondary mouse xenograft possessed
all of the mutations, including heterozygous TP53 and
PALB2 mutations, and most likely derived from two of
themost evolved subclones in the neurospheres (being pre-
sent in only 3.3% and 4%, respectively; Figure 4B). The
Figure 1. Subclonal Genetic Structure of Neurosphere Cells and Tumor-Propagating Cells Derived from Primary Tumor GBM 2
(A–C) SNP 6 array profiles of DNA from GBM 2 primary tumor showing high-level PDGFRA amplification (A), whole chromosome 7 gain (B),
and high-level MDM2 amplification (C).
(D) Subclonal genetic structure in the neurospheres (top) and after secondary transplantation in a single mouse (m3) (bottom). Subclones
represented by gray circles were not present in the neurospheres above the threshold detection level. FISH images are shown next to their
respective genotype. Red type indicates the major clone. Solid arrows show probable derivation of subclones. Dashed arrows indicate
possible alternative derivation of subclones. FISH images were captured at 1003 magnification.
See also Figure S1 and Tables S1, S2, S3, and S4.
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copies of EGFR evolved further in the xenograft cells by
acquiring two mutated copies of TP53, and all subclones
evolved to show high-level amplification of EGFR (>100
copies) (Figure 4B).
We used secondary transplantation as a more stringent
measure of stem cell renewal (Dick et al., 1997). In five cases
(GBM1,GBM5,GBM8,GBM9, andGBM11), we observed
a statistically shorter time to tumor formation in the sec-
ondary transplant than in the primary xenograft tumor.SThis pattern of evolution is consistent with the typical
pattern of disease progression seen in patients and would
be consistent with the genetically more evolved subclonal
structure observed in the neurospheres of GBM 5, GBM 8,
and GBM 11, and with the presence of TP53mutations in
GBM 5 and GBM 8.
Clones with EGFR amplification consistently read out
after serial transplantation, and usually further evolved
with an incremental gain ofmore copies of EGFR. Other in-
vestigators have demonstrated a mosaic pattern of growthtem Cell Reports j Vol. 4 j 7–15 j January 13, 2015 j ª2015 The Authors 9
Figure 2. Subclonal Genetic Structure of Neurosphere Cells and Tumor-Propagating Cells Derived from Primary Glioblastoma
GBM 11
(A–C) SNP 6 array profiles of DNA from GBM 11 primary tumor showing PDGFRA amplification (A), high-level EGFR amplification (B), and
homozygous CDKN2A deletion (C) comprised of a large deletion of one allele (box) and focal deletion of the second allele (arrow).
(D) Subclonal structure of neurosphere cells (top) and tumor cells after secondary transplant in a single mouse (m3) (bottom). Potentially
three different CDKN2A deletions occur in different subclones in the neurospheres (indicated by boxes). Solid arrows show probable
derivation of subclones. Dashed arrows indicate possible alternative derivation of subclones. FISH images were captured at 1003
magnification.
See also Figure S1 and Tables S1, S2, S3, and S4.
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PDGFRA gain occurring in distinct populations of cells
(Snuderl et al., 2011; Szerlip et al., 2012). In the present
study, there was one case (GBM 11) with subclones in the
neurosphere cells that showed concurrent PDGFRA and
EGFR gain in the same cell, as well as subclones with
only EGFR gain (Figure 2). However, only the subclones
with high-level EGFR amplification repopulated themouse
xenograft; none of the subclones with PDGFRA gain were10 Stem Cell Reports j Vol. 4 j 7–15 j January 13, 2015 j ª2015 The Authorspresent. These observations reveal the dynamic complexity
of subclonal interactions in GBM and provide deeper
insight into the role of PDGFRA. We previously showed
that amplification of PDGFRA occurs in the midphase
of GBM evolution (Sottoriva et al., 2013) rather than as
a primary driver event. Evidence suggests that tumor-prop-
agating clones may arise from a common precursor,
with key early events including genetic alterations in
EGFR, CDKN2A/B, and TP53 (Goodenberger and Jenkins,
Figure 3. Identical Subclonal Genetic Structure of Neurosphere Cells and Tumor-Propagating Cells Derived from Primary Tumor
GBM 8
(A–C) SNP 6 array profiles showing chromosome 7 (A), focal PTEN loss (B), and a large deletion of chromosome 13, including RB1 (C). There
was also loss of heterozygosity (LOH) for the whole of 17p (including the TP53 gene) without any copy number change (uniparental disomy
[UPD]).
(D) FISH analysis of GBM 8 neurospheres using a range of centromere probes revealed that these were nearly triploid, with two PTEN and
RB1 signals corresponding to a loss of one copy of each locus. The neurospheres showed a branched subclonal structure with four subclones
above the FISH detection threshold (2%) at the time of injection into primary mice (top). All of these read out in the tumors of at least one
secondary transplanted mouse (bottom). One further subclone detected in all mice was present in the neurospheres at a level below the
cutoff for FISH (1.8%) (box). m1, m2, m3: three replicate mice, each injected with 1 3 106 neurosphere cells. Solid arrows show the
probable derivation of subclones. Dashed arrows indicate the possible alternative derivation of subclones. FISH images were captured at
1003 magnification.
See also Figure S1 and Tables S1, S2, S3, and S4.
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Figure 4. Single-Cell Analysis of Selected
Mutations and CNAs Identified by Exome
Sequencing in GBM 5
(A and B) Subclonal genetic architecture
in neurospheres (A) and tumor-propagating
cells derived from GBM 5 after xeno-
transplantation (B, mouse 2). A total of 240
neurosphere cells and 100 cells from the
secondary xenotransplant tumor were evalu-
ated. Mutations and CNAs are given within
the circles; additional mutations and CNAs in
individual subclones are indicated in red.
See also Figures S2–S4 and Tables S1, S2, S3,
and S4.
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Subclonal Genetic Diversity in Glioblastoma2012; Snuderl et al., 2011; Sottoriva et al., 2013). These
observations are supported by data from glioma suscepti-
bility studies that revealed prominent roles for alterations
in EGFR, CDKN2A, and TP53 in glioma evolution (Ander-
sson et al., 2010; Egan et al., 2012; Shete et al., 2009; Stacey
et al., 2011; Wrensch et al., 2009).
Our data confirm previously unrecognized levels of
temporal diversity and complexity in the subclonal land-
scape of GBM. In all cases analyzed, genetically distinct
subclones had variable serial repopulating activity in vivo.
We can exclude the possibility that the presence of in vitro
aberrations played a role in the clonal architecture of the
mouse xenografts, given the culture conditions used and
the number of in vitro cell passages. Since the in vivo
readout is likely to be a functional activity of self-renewing
CSCs, this suggests that the competitive self-renewal ability
of tumor-propagating stem cells in GBM varies on the basis
of frequency and/or quantitative features (e.g., prolifera-
tion rates and growth factor dependence). This is in line
with the principle that the extensive replicative potential
of CSCs allows subclonal evolution (Greaves and Maley,
2012).
Our interrogation of subclonal genetic diversity of hu-
man GBM has revealed that tumor-propagating cells in
GBM are genetically heterogeneous and have a variable
competitive capacity for tumor propagation in vivo. The
link forged among genetic diversity, clonal architecture,
and propagating activity in vivo may facilitate the charac-
terization of mutational variants that are responsible for
disease recurrence and therapeutic resistance in patients
(Johnson et al., 2014).EXPERIMENTAL PROCEDURES
GBM Sample Collection
Twelve patients diagnosed with primary GBM were administered
5-aminolevulinic acid (Medac UK) 5 hr before surgery as an oral
dose of 20 mg/kg as previously described (Piccirillo et al., 2012;
Stummer et al., 2006). The tissue collection protocols complied
with the UK Human Tissue Act 2004 (HTA license ref. 12315)
and were approved by the local regional ethics committee (LREC
ref. 04/Q0108/60). Informed consent was obtained from each pa-
tient before surgery.
Cell Line Derivation and In Vivo Tumorigenicity
Primary culture and neurosphere cell line derivation were per-
formed as previously described (Fael Al-Mayhani et al., 2009; Picci-
rillo et al., 2009, 2012). Briefly, primary GBM cells were plated in
culture dishes directly after tumor resection from the patient and
used for in vivo experiments upon formation of the first neuro-
spheres. To evaluate in vivo tumorigenicity, serial transplantations
(two in vivo passages) were performed using immunosuppressed
animals. As soon as neurosphere cultures were established, me-
chanical dissociation to single cells was carried out and 1 3 106Stecells/animal were used for intracerebral transplantation into the
right striatumof 4-week-oldNOD-SCIDmice (Charles River), using
previously described stereotactic coordinates (Piccirillo et al., 2006,
2009). From the same single-cell suspension, 1 3 106 cells were
used for FISH analysis.
In total, 36 animals were injected with cells derived from
12 GBMs (n = 3 animals/GBM). Mice were sacrificed when
they became symptomatic according to the Home Office guide-
lines. Whole mouse brains were removed and tumors were re-
sected as previously described (Galli et al., 2004). The tissue was
mechanically disaggregated and reinjected into other 4-week-old
NOD-SCID mice using the same stereotactic coordinates (n = 3
animals/GBM, 34 animals in total). When symptoms appeared,
the animals were sacrificed and the whole tumors were resected
and disaggregated. All of the tumors harvested from mice after
the secondary in vivo passage were used in FISH analyses for com-
parison with the single-cell suspension derived from neurosphere
cultures. Disaggregated cells from the primary xenograft tumors
were fixed for FISH and stored for comparison if needed. All of
the in vivo experiments were performed according to UK Project li-
cense approval.
FISH
Single-cell suspensions from dissociated neurosphere cultures
or mouse xenograft tumor mice were harvested and fixed in meth-
anol-acetic acid according to standard cytogenetic methods (Hors-
ley et al., 2008). Then, 100–200 nuclei from each cell preparation
were analyzed for the presence of the relevant FISH probes sig-
nals. Interphase FISH for selected CNAs was carried out as previ-
ously described (Anderson et al., 2011) using BAC and fosmid
probes for selected genes (the BACPACResource Center, Children’s
Hospital, Oakland Research Institute; http://bacpac.chori.org).
Probes were labeled by nick translation with biotin-16-dUTP
(Roche Diagnostics), SpectrumGreen (Vysis, Abbott Laboratories),
or Cy3-dUTP (Roche Diagnostics), and hybridized in combination
as previously described (Anderson et al., 2011). Hybridization and
washes were performed according to the Vysis protocol, with a
single layer of Cy5-conjugated streptavidin (GE Healthcare) for
detection of biotinylated probes. Fluorescent signals were viewed
with a Zeiss Axioskop fluorescence microscope equipped with
filters for DAPI, fluorescein isothiocyanate/SpectrumGreen, Spec-
trumOrange, and Cy5. Images were captured and analyzed using
a Hamamatsu ORCA-ER CCD camera and SmartCapture X soft-
ware (Digital Scientific).
Whole-Exome Sequencing
Genomic DNAwas subjected to whole-exome sequencing (Oxford
Gene Technology). Exome capture was performed using the Sure-
SelectXT Human All Exon v4 kit (Agilent) according to manufac-
turer’s instructions and sequenced with Illumina paired-end
sequencing (protocol v1.2).
Single-Cell Analysis
Single-cell sorting, qPCR, and analysis were all performed essen-
tially as previously described (Potter et al., 2013). Briefly, single
cells were sorted on a BDFACSAria1-SORP instrument (BD) directly
into lysis buffer. Specific (DNA) targeted amplification was thenm Cell Reports j Vol. 4 j 7–15 j January 13, 2015 j ª2015 The Authors 13
Stem Cell Reports
Subclonal Genetic Diversity in Glioblastomaperformed prior to qPCR. Single-cell, target-amplified DNA was
interrogated by qPCR for each DNA target of interest using the
96.96 dynamicmicrofluidic array and the BioMarkHD system (Flu-
idigm) as recommended by the manufacturer.
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